molaxole powder for oral solution
viatris healthcare limited - macrogol 3350; sodium chloride; sodium hydrogen carbonate; potassium chloride - powder for oral solution - osmotically acting laxatives; macrogol, combinations
molaxole powder for oral solution
mylan ire healthcare limited - macrogol 3350; sodium chloride; sodium hydrogen carbonate; potassium chloride - powder for oral solution - 13.125/350 milligram(s) - osmotically acting laxatives; macrogol, combinations
molaxole powder for oral solution
primecrown 2010 limited - sodium chloride; sodium hydrogen carbonate; macrogol 3350; potassium chloride - powder for oral solution - osmotically acting laxatives; macrogol, combinations
molaxole 13.125/350 powder for oral solution
meda health sales ireland limited - macrogol 3350, sodium chloride, sodium bicarbonate, potassium chloride - powder for oral solution - 13.125/350 - osmotically acting laxatives
co-trimoxazole 960mg tablets
dawa limited - sulfamethoxazole/trimethoprim - tablets - 800mg/160mg - combinations of sulfonamides and trimethoprim, incl. derivatives - indicated for the treatment of the following infections in adults and adolescents when owing to sensitive organisms (see section 5.1): treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis treatment and prophylaxis of toxoplasmosis treatment of nocardiosis the following infections may be treated with co-trimoxazole tablets where there is bacterial evidence of sensitivity to co-trimoxazole tablets and good reason to prefer the combination of antibiotics in co-trimoxazole tablets to a single antibiotic: acute uncomplicated urinary tract infection acute otitis media acute exacerbation of chronic bronchitis
co-trimoxazole 80mg/400mg tablets
aspen pharma trading ltd - sulfamethoxazole; trimethoprim - oral tablet - 400mg ; 80mg
co-trimoxazole 80mg/400mg tablets
accord-uk ltd - sulfamethoxazole; trimethoprim - oral tablet - 400mg ; 80mg
co-trimoxazole 240 mg/ml solution for injection for cattle.
kela n.v. - sulfamethoxazole; trimethoprim - solution for injection - 24 percent weight/volume - combinations of sulfonamides and trimethoprim, incl. derivatives - cattle - antibacterial
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
kaiser foundation hospitals - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. ac
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
glenmark generics inc. usa - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute ot